CoreAge Rx vs Prime Doctor RX
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Prime Doctor RX head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
Prime Doctor RX
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 70 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Prime Doctor RX a bad call — it's best for a reader who will convert every figure into four-week cycles before comparing it with anything else. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Prime Doctor RX | |
|---|---|---|
| Brief Score | 94/100 (A) | 70/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $249 every 4 weeks (compounded) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $339 every 4 weeks (compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | Confirmed at intake, not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Prime Doctor RX: New to the tracker on 13 September 2026, read live off the provider's own pages that day rather than taken on trust. There is no earlier reading here to compare against, so the direction is "new" rather than stable — a first observation is not a trend. The number that will move here is the one nobody prints: a 28-day cycle means thirteen charges a year, so every figure on this page is 8.3% more annually than its label implies.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.